Key result
Breast reconstruction after HER2-targeted chemotherapy linked to severe heart failure with LVEF dropping to 28%.
Case Report (n=1)
No
This case highlights the critical need for early detection and management of cancer treatment-related cardiac dysfunction to prevent fatal complications and allow continuation of necessary cancer therapies.
Answers are grounded in this paper and cite their sources.
Severe LVEF drop post-reconstruction after HER2 therapy warrants perioperative monitoring; single case leaves open surgery's role in cardiotoxicity.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
ADACHI et al. (2025) conducted a case report in HER2-positive breast cancer (n=1). Adjuvant chemotherapy (EC followed by docetaxel, pertuzumab, trastuzumab) and breast reconstruction surgery was evaluated on Development of cancer treatment-related heart failure. A 49-year-old woman with HER2-positive breast cancer developed cancer treatment-related heart failure with LVEF dropping from 66% to 28% after breast reconstruction surgery following chemotherapy.
Synapse has enriched 10 related papers. Consider them for comparative context: